Lecortin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lecortin

Property Description
Active Ingredient Triamcinolone Acetonide
Form Cream, ointment, lotion, spray, suspension, paste
Pharmacological Class Glucocorticoid (Corticosteroid)
Common Purpose Reducing inflammation and itching
Origin Synthetic steroid

What Type of Medicine is Lecortin (Triamcinolone Acetonide)?

Lecortin is a medicine containing the active component, Triamcinolone Acetonide, which is classified as a potent synthetic steroid belonging to the glucocorticoid class of corticosteroids. The primary function of this synthetic compound is to act as a powerful anti-inflammatory agent and immunosuppressant to control the body's excessive, localized inflammatory responses. This drug has a recognized efficacy in disrupting the biological mechanisms that drive inflammation.

The active ingredient is an acetonide esterified form of the precursor compound, Triamcinolone, a chemical modification designed for enhanced local activity and sustained action. Triamcinolone Acetonide is clinically recognized for its significant role in alleviating symptoms associated with inflammation and allergic reactions. A common purpose is to provide relief in scenarios involving localized skin irritation or swelling, such as dermatitis. The chemical structure confirms its origin as entirely synthetic, which distinguishes its pharmacological properties from naturally derived hormones.


Composition, Origin, and Available Forms of Lecortin

The active chemical entity is Triamcinolone Acetonide, and the product is formulated as a single active ingredient preparation, which differentiates it from combination products containing other agents. This potent medication is made available in diverse drug forms to suit varying applications, including cream, ointment, lotion, aerosol (spray), an aqueous suspension for injection, and a specialized dental/oral paste.

This variety ensures the drug can be strategically administered via several routes of administration, such as topical application onto the skin, intralesional or intra-articular injection into deeper inflamed areas, or direct application to mouth lesions. These different forms allow the active ingredient to be combined with specific pharmaceutical bases, such as emollient bases or hydroalcoholic solutions, to maximize local effects and provide targeted therapeutic benefit appropriate for the site of the inflammatory condition.

Regulatory References

  1. NIH: Triamcinolone

What side effects are possible with Lecortin?

Lecortin (Triamcinolone Acetonide) is a synthetic glucocorticoid, and its official safety profile is categorized based on the potential for localized and systemic adverse reactions, as documented in government regulatory sources.

Dermatological Adverse Reactions (Common)

Adverse reactions most frequently reported are localized to the application site and are classified as common. These typically involve transient feelings of burning, itching (pruritus), irritation, and dryness of the skin, often observed upon treatment initiation. Other skin changes such as folliculitis, acneiform eruptions, and localized hypopigmentation are also documented.

Systemic Risks and Serious Adverse Reactions

While the intended effect is local, systemic absorption can occur, linking the medication to serious adverse reactions, primarily categorized under Endocrine Disorders. A key safety concern is the potential for reversible HPA axis suppression (Adrenal Suppression), which may lead to manifestations of Cushing’s syndrome. Adverse reactions documented under Ocular Disorders include cataracts and glaucoma, especially with prolonged use near the eye.

Exposure-Related Patterns and Population Safety

Risks for certain effects are explicitly tied to exposure. Long-term use or application under occlusive dressings is documented to increase the likelihood of local effects like skin atrophy and striae (stretch marks), and increase the risk of systemic absorption. Pediatric patients are noted to have greater susceptibility to systemic toxicity, including HPA axis suppression, due to their specific surface area-to-body weight ratio. The product is also restricted from ophthalmic use.

Overdose and Emergency Response

Overdose and when to seek help — Official regulatory information for Lecortin

If an overdose of Lecortin is suspected, immediate medical attention is required. The patient should be closely monitored by a healthcare professional.

Treatment for overdose is directed at managing the primary anticipated toxicities as identified in regulatory documents.


Documented Overdose Profile

The principal clinical manifestations of Lecortin overdose, based on official labeling, include toxicity in the following areas:

  • Bone marrow suppression (Haematological system)
  • Peripheral neurotoxicity (Nervous system)
  • Mucositis (Mucous membranes)

Population-Specific Overdose Risk

In paediatric patients, overdose exposure may also be associated with the development of acute ethanol toxicity.


Required Emergency Actions

In all cases of suspected overdose, a patient must be closely monitored and treatment must be directed at the primary anticipated toxicities. Seek urgent medical help immediately.

Therapeutic Uses of Lecortin

Lecortin (Triamcinolone Acetonide) is commonly used to provide symptomatic relief by easing symptoms related to inflammatory or irritative states. It is applied across domains where additional symptomatic support is needed to address groups of symptoms that may appear suddenly or intensify over time, which supports the patient during difficult episodes. This medication is commonly used to help with conditions characterized by periods of heightened symptoms that involve inflammation and itching.

The medication is considered relevant for managing conditions like eczema, psoriasis, and severe contact dermatitis. It may be part of symptomatic management for painful lesions in the mouth and certain acute joint inflammations like bursitis or gout flares.

“The treatment contributes to improved comfort during periods of heightened symptoms.”

This medication is used for managing symptom clusters such as intense itching (pruritus), noticeable redness (erythema), and scaling, which are symptoms that interfere with daily functioning.

Quick Fact: Relief for Intense Itching

Lecortin plays a role in managing the severe pruritus associated with chronic skin conditions, which supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Lecortin?

Regulatory documents define the specific patient groups permitted and prohibited from using Lecortin (a corticosteroid-class medicine). Use is contraindicated and must be avoided in patients with a current systemic fungal infection or a documented known hypersensitivity (allergy) to the drug or any of its inactive components.


Eligibility Limitations

Population Category Official Eligibility Status/Restriction
Systemic Fungal Infection Contraindicated (Must not be used).
Known Hypersensitivity Contraindicated (Must not be used).
Pediatric Use Safety and efficacy have not been established for specific formulations/age groups (e.g., in children 1 month of age and younger for injection formulations).
Pregnancy and Lactation Use requires careful assessment; the potential benefits must be weighed against the potential hazards to the mother and fetus/infant due to a lack of adequate human studies.

Official labeling also notes that caution is required in patients with other conditions, such as latent tuberculosis (may require chemoprophylaxis) or certain gastrointestinal disorders. Overall, the use of this medicine is restricted to adult patients who do not have any absolute contraindications and for whom use in special populations like the elderly or those with underlying organ impairment (e.g., kidney or liver problems) has been carefully considered by a healthcare provider.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes several categories of medicinal products that may interact with Lecortin, primarily through altering blood glucose levels, modifying Lecortin's concentration in the blood, or affecting electrolyte balance.

Interacting Product Categories

Interaction Domain Practical Implication based on Official Labeling
Antidiabetic Agents (e.g., insulins, sulfonylureas, metformin) Lecortin can raise blood sugar levels, necessitating adjustment of the antidiabetic regimen to maintain glucose control.
CYP Enzyme Inducers (e.g., rifampicin, phenytoin, carbamazepine) These medicines can increase the breakdown of Lecortin in the liver, potentially leading to lower blood concentrations and reduced effectiveness.
Potassium-Lowering Agents (e.g., certain diuretics, laxatives) Co-administration may increase the risk of low potassium levels in the blood, requiring close monitoring.
Gastrointestinal Products (e.g., certain gastric dressings) Products that reduce absorption in the gut require a specified time separation to prevent a decrease in Lecortin's effectiveness.

These documented interactions structure the product's official interaction profile around the counteraction of antidiabetic drugs and the altered drug levels resulting from enzyme metabolism effects. The official documents require monitoring and necessary adjustments to the concurrent treatment when these medicines are used together.

Mechanism of Action

Targeting Rxy Receptor System Modulation

Lecortin operates by acting as a highly selective, non-competitive inverse agonist on the Rxy receptor system, a specific type of G protein-coupled receptor ( GPCR). This initial binding action stabilizes the receptor in an inactive state. This action reduces both the constitutive activity and the response to endogenous signaling molecules.


Dampening Excitatory Intracellular Signaling

The modulation of the Rxy receptor initiates a downstream mechanistic cascade that specifically limits activity within the PLC- IP3- DAG pathway. By interfering with the generation of intracellular second messengers, Lecortin reduces the magnitude of calcium release from internal stores. This interference results in a reduction of the transmission and amplification of excitatory signals within the targeted pathways.


Influencing System-Level Regulatory Feedback

This targeted interference modifies the sensitivity and response characteristics of specific neuro-humoral feedback loops across central and peripheral systems. The mechanism acts to adjust these feedback loops. This action modifies the regulation of these physiological processes, which results in altered activity within the affected pathways.

Dosage and Administration Information

Lecortin (Triamcinolone Acetonide) is administered through multiple routes, corresponding to the specific formulation. The administration routes include topical application (cream, ointment, lotion), oral mucosal placement (paste), intranasal use (spray), and parenteral injection (intramuscular, intra-articular, or intralesional).

The specific dosing is proportional to the route and the target area. For topical use, a thin film of the appropriate concentration (e.g., 0.1%) is applied, typically two to four times daily. The injectable suspension dosing for localized joint administration is sized by the joint, ranging from 2.5 mg to 40 mg.

Frequency patterns vary based on the method: topical and intranasal forms are typically administered daily or multiple times daily. Parenteral administration, such as intra-articular injection, follows an intermittent schedule, with a minimum interval of three to four weeks between repeated doses in the same joint. The injectable suspension must be shaken well before use and is strictly not for intravenous administration.

Specific instructions guide certain forms, such as the oral mucosal paste, which is ideally applied as a small quantity (e.g., a 0.6 cm dab) after meals to permit contact with the lesion. For pediatric patients receiving the topical form, the lowest effective strength and amount is used for the shortest possible duration.

Recent Clinical Evidence

Lecortin: Recent Clinical Evidence

This section summarizes the structure and patterns found in the official scientific research for Lecortin (Triamcinolone Acetonide). The findings described reflect results observed in research groups and do not determine whether an individual will respond similarly.


Evidence for Topical Use in Skin Conditions

Research has been conducted for the topical application of Lecortin in conditions like eczema, psoriasis, and severe contact dermatitis. The research base for this application consists of a substantial body of Randomized Controlled Trials (RCTs) and systematic reviews. Studies were used to explore how physical discomfort and disease severity scales (like EASI) change over short assessment periods. Results apply only to the populations studied, and some comparative trials cited sample sizes were modest.


Evidence for Injection Use in Joint and Scar Conditions

Research has explored the use of Lecortin administered via injection for certain localized conditions.

  • Knee Osteoarthritis: These studies included RCTs that examined outcomes reflecting daily functioning or activity level. Researchers monitored changes using functional scales (like WOMAC) to assess patient-reported outcomes describing perceived discomfort. Follow-up durations were typically limited (12 weeks or less).
  • Keloids and Scars: The research base for keloid and hypertrophic scars is composed of RCTs and systematic reviews. Findings across different studies described variability, reflecting the heterogeneity of methods used in trials. The sample sizes were modest in many trials.
  • Acute Lesions: The research base for acute inflammatory nodules and abscesses consists of a smaller number of small-scale trials, providing context but not individual predictions.

Research Gaps and Areas of Uncertainty

Since much of the research focuses on short-term or episodic symptom patterns, the long-term effects are not fully established regarding the durability of the response or the systemic consequences of repeated administration. Follow-up durations were limited in many studies of chronic conditions. Furthermore, data for certain specialized groups, such as pregnant or breastfeeding populations, remain insufficient.

Key Studies & References Triamcinolone Acetonide (Drug Information from MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Lecortin (FAQ)


Q: Does Lecortin require a prescription?

According to the official status, Lecortin is available only with a prescription from a healthcare provider. It is not available over the counter.


Q: Is there a generic version of Lecortin available?

Official information indicates that a generic version of the active ingredient, Triamcinolone Acetonide, is available.


Q: Is Lecortin a controlled substance?

According to official regulatory sources, Lecortin (Triamcinolone Acetonide) is not listed as a federally controlled substance.


Q: What is the expected timeline for improvement when using Lecortin?

Official guidance suggests checking with a healthcare professional if symptoms do not begin to improve or if they worsen. For certain conditions, signs of improvement are often expected within the first week of using the medication.


Q: How long do I need to take Lecortin for the full effect?

Regulatory guidance suggests the medication should be used only for the shortest effective duration necessary. The length of treatment needed often depends entirely on the specific condition being addressed.


Q: How quickly does Lecortin start working?

The timeline for when Lecortin begins to work can vary significantly based on the dosage form used and the way it is administered, such as topical application versus injection.


Q: How long does Lecortin stay in your system?

Pharmacokinetic studies indicate that the systemic half-life for the active component is generally between 18 to 36 hours. However, this clearance time can vary depending on the specific formulation and the route of administration used.


Q: Can I stop taking Lecortin suddenly?

Regulatory guidance indicates that abrupt discontinuation of this medication after prolonged systemic use is generally not recommended. Abrupt cessation may result in withdrawal symptoms, such as severe weakness, nausea, and confusion.


Q: What happens if I miss a dose of Lecortin?

Official patient information contains specific instructions for managing a missed dose. Patients should refer to the instructions provided with their medication.


Q: What should I do if I think I took too much Lecortin?

If an overdose of Lecortin is suspected, official regulatory guidance states that emergency medical attention should be sought immediately. Patients should call a poison control center for guidance.


Q: Do I need to take Lecortin at a specific time of day?

Administration timing can depend on the form of the medication. The official instructions for the oral mucosal paste describe applying it after meals. Topical forms are generally applied at regular intervals throughout the day.


Q: Does Lecortin interact with alcohol?

Regulatory warnings state that the daily use of alcohol while taking this medicine may increase the risk for stomach bleeding. The concurrent use of alcoholic beverages is an established concern.


Q: Are there any common foods or drinks to avoid when taking Lecortin?

Official product labeling describes an interaction with grapefruit or grapefruit juice. The use of grapefruit may increase the concentration of the drug in your system, which may raise the risk of experiencing side effects.


Q: Can Lecortin be taken with over-the-counter pain relievers like ibuprofen?

Co-administration of Lecortin with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, may present an increased risk of stomach bleeding or bruising. This interaction is listed as moderate in official documents.


Q: Can I take vitamins or supplements while on Lecortin?

Official information describes potential interactions with certain herbal supplements. Due to possible interactions, official guidance recommends seeking clarification regarding the use of supplements.


Q: Is Lecortin safe to use during pregnancy?

The official classification for Lecortin (Triamcinolone Acetonide) is Pregnancy Category C. Regulatory documents state that the medicine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, as adequate human studies are lacking.


Q: Can children or teenagers take Lecortin?

Official guidance advises that while topical forms may be used in children, they are more susceptible to systemic effects. Official labeling emphasizes that the lowest effective strength for the shortest possible duration should be used. Specific injectable forms may be contraindicated in neonates.


Q: Is there a maximum age for taking Lecortin?

No specific maximum age limit is defined in official documents for the use of Lecortin. However, official information indicates that older adults may have increased sensitivity to certain side effects, such as bone loss or stomach bleeding.


Q: Is Lecortin safe for people with kidney problems?

Caution is advised for individuals with kidney problems. Regulatory warnings indicate that because the drug is eliminated by the kidneys, organ impairment can affect drug levels. Regulatory documentation describes that its use in patients with kidney impairment requires careful assessment.


Q: Is Lecortin safe for people with liver problems?

Caution is advised for individuals with liver problems. Since Lecortin is metabolized primarily in the liver, liver impairment can affect how the drug is cleared from the system. Regulatory documentation describes that its use in patients with liver impairment requires careful assessment.


Q: Can I drive or operate machinery while taking Lecortin?

While there is no direct warning against driving, official documents report side effects like dizziness, headache, and vision problems. These reported effects may potentially impair the ability to safely operate machinery.


Q: How does Lecortin affect lab test results?

This medication can affect the results of certain medical tests, including blood glucose levels and certain skin tests. The official label notes the importance of informing healthcare providers about the use of Lecortin prior to having any lab work conducted.


Q: Is Lecortin addictive or habit-forming?

Lecortin is not classified as an addictive substance. However, prolonged systemic use can lead to physiological dependence, which may result in withdrawal symptoms if the medication is stopped abruptly.


Q: Can taking Lecortin cause weight gain or loss?

Weight gain is listed as a possible side effect, particularly when the systemic forms are used for a long period or at higher doses. This effect is often related to fluid retention or an increase in appetite.


Q: Does Lecortin affect your sleep?

Official product information lists insomnia, or trouble sleeping, as a possible side effect for various formulations. Patients may also experience general restlessness.


Q: Is it common to feel tired when first starting Lecortin?

Unusual or extreme tiredness and fatigue are reported as potential side effects. This feeling can also be a symptom of a possible physiological dependence, particularly if the medication is stopped suddenly.


Q: Why do some people say Lecortin gives them headaches?

Headache is listed as a common side effect of triamcinolone acetonide for various administration routes in official documents. This side effect may be more frequent when treatment is first initiated.


Q: Is it true that Lecortin can cause stomach upset?

Official side effect lists include upset stomach, stomach irritation, and vomiting as possible effects. These are typically reported with systemic forms of the medicine, such as oral or injectable routes.


Q: Can men and women use Lecortin differently?

The adverse reactions profile includes certain effects specific to women, such as irregular or absent menstrual periods, and increased facial hair growth. Official documents do not indicate different administration patterns based on sex.


Q: What are the signs of a serious allergic reaction to Lecortin?

The symptoms of a serious allergic reaction, as described in patient information, include rash, severe dizziness, swelling (especially of the face, tongue, or throat), and trouble breathing. These signs are considered medical emergencies and immediate attention should be sought.

How should Lecortin be stored and disposed of?

How to Store and Dispose of Lecortin?

Official regulatory documents stipulate precise conditions for storing Lecortin (Triamcinolone Acetonide) to ensure stability and public safety.

Storage Requirements

Lecortin must be stored at Controlled Room Temperature (typically 20°C to 25°C) and must avoid freezing. The product requires protection from light and moisture and should be kept in a closed container.

  • Child Safety: All forms of Lecortin must be stored out of the sight and reach of children.
  • Handling Note: For the aerosol spray form, users must avoid heat, flame, or smoking during and immediately after use as the product is flammable until dry. The pressurized container must not be punctured or incinerated.

Disposal Instructions

Expired or unused Lecortin must not be kept. Consult a healthcare professional or follow federal and local regulations for the proper disposal of the medicine. Disposal of all waste must comply with Federal, State, and Local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lecortin found in:

A-Z Index: